Abstract
Serum Beta-Trace Protein and Cystatin C as Biomarkers for Renal Dysfunction in Patients with Chronic Kidney Disease
Highlights
Chronic Kidney Disease (CKD) is a broad term used to describe any abnormality of kidney structure or function
In comparison with the healthy control group, patients undergoing hemodialysis had the maximum elevated levels of serum urea and creatinine and the noticed values were 125 and 9.96 mg/dl, respectively, while, estimated GFR (eGFR) level declined to 9.8 ml/min
The current study aims to estimate the clinical efficacy of the serum levels of cystatin C (Cys-C) and beta-trace protein (BTP) for the early detection of renal dysfunction in patients with CKD
Summary
Chronic Kidney Disease (CKD) is a broad term used to describe any abnormality of kidney structure or function. It is associated with an increased risk of end-stage renal failure. CKD is a decreased kidney function and characterized by a glomerular filtration rate (GFR) less than 60 mL/min/1.73 m2 [1]. Serum creatinine is a basic marker of GFR in spite of its numerous well-known restrictions. The serum concentration of creatinine is reliant on various non-renal factors such as gender and muscle mass [2]. It was used for many decades to assess the kidney function, it noticed that this marker isn’t perfect and accurate [3]. The requirement for new biomarkers for monitoring kidney function in patients with CKD was demanded
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
